Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (Jun 2021)

Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction

  • Rohan Samson,
  • Thierry H. Le Jemtel

DOI
https://doi.org/10.1161/JAHA.121.021120
Journal volume & issue
Vol. 10, no. 12

Abstract

Read online

Abstract The findings of randomized trials of neurohormonal modulation have been neutral in heart failure with preserved ejection fraction and consistently positive in heart failure with reduced ejection. Left ventricular remodeling promotes the development and progression of heart failure with preserved and reduced ejection fraction. However, different stimuli mediate left ventricular remodeling that is commonly concentric in heart failure with preserved ejection fraction and eccentric in heart failure with reduced ejection. The stimuli that promote concentric left ventricular remodeling may account for the neutral findings of neuhormonal modulation in heart failure with preserved ejection fraction. Low‐grade systemic inflammation‐induced microvascular endothelial dysfunction is currently the leading hypothesis behind the development and progression of heart failure with preserved ejection fraction. The hypothesis provided the rationale for several randomized controlled trials that have led to neutral findings. The trials and their limitations are reviewed.

Keywords